HCV NS4A Protein (21_34) (JT strain) Formula C63H116N20O17 Sequence Gly_Ser_Val_Val_I le_Val_Gly_Arg_Ile_Ile_Leu_Ser_Gly_Arg
- Known as:
- Hepatitis C virus NS4A Protein (21_34) (JT strain) Formula C63H116N20O17 Sequence Gly_Ser_Val_Val_I le_Val_Gly_Arg_Ile_Ile_Leu_Ser_Gly_Arg
- Catalog number:
- 89119
- Product Quantity:
- 5mg
- Category:
- -
- Supplier:
- GLSChina
- Gene target:
- HCV NS4A Protein (21_34) ( strain) Formula C63H116N20O17 Sequence Gly_Ser_Val_Val_I le_Val_Gly_Arg_Ile_Ile_Leu_Ser_Gly_Arg
Related genes to: HCV NS4A Protein (21_34) (JT strain) Formula C63H116N20O17 Sequence Gly_Ser_Val_Val_I le_Val_Gly_Arg_Ile_Ile_Leu_Ser_Gly_Arg
- Gene:
- SAP30L NIH gene
- Name:
- SAP30 like
- Previous symbol:
- -
- Synonyms:
- FLJ11526, NS4ATP2
- Chromosome:
- 5q33.2
- Locus Type:
- gene with protein product
- Date approved:
- 2006-03-24
- Date modifiied:
- 2016-07-12
- Gene:
- SPATA20 NIH gene
- Name:
- spermatogenesis associated 20
- Previous symbol:
- -
- Synonyms:
- FLJ21347, SSP411, Tisp78
- Chromosome:
- 17q21.33
- Locus Type:
- gene with protein product
- Date approved:
- 2005-05-25
- Date modifiied:
- 2019-03-19
Related products to: HCV NS4A Protein (21_34) (JT strain) Formula C63H116N20O17 Sequence Gly_Ser_Val_Val_I le_Val_Gly_Arg_Ile_Ile_Leu_Ser_Gly_Arg
Paliperidone N-Oxide CAS: 761460-08-6 Formula: C23H27FN4O4 2,4-Dibromo-17,17-ethylenedioxy-1,3,5(10)-estratriene-3,16α-diol CAS: 90474-20-7 Formula: C20H24Br2O4 2,4-Dibromo-17,17-ethylenedioxy-1,3,5(10)-estratriene-3-ol CAS: Formula: C20H24Br2O3 3,3',5,5'-Tetraiodo Thyroformic Acid CAS: 2055-97-2 Formula: C13H6I4O4 3,5,3',5'-Tetrachlorobisphenol A CAS: 79-95-8 Formula: C15H12Cl4O2 4-(2,6,6-Trimethyl-2-cyclohexen-1-ylidene)-2-acetoxybut-2-ene CAS: 61693-39-8 Formula: C15H22O2 4-Benzyloxy-1-cyclohexanecarbonitrile (cis / trans mixture) CAS: 95233-32-2 Formula: C14H17NO 5-[(4-Methoxyphenyl)-diphenylmethylamino-6-methoxy-9H-purin-9-yl]-13C2, 15N-3-(phenylmethoxy)-2-[(phenylmethoxy)methyl]-cyclopentanol CAS: Formula: 6-Phenylhexylamine Hydrochloride CAS: 120375-57-7 Formula: C12H20ClN Paliperidone-d4 CAS: 1020719-55-4 Formula: C23H23D4FN4O3 guanine nucleotide binding protein alpha inhibiting activity polypeptide 1 (GNAI1) polyclonal antibody"Affordable Gel Doc System with UV, Epi white & white
backlight Source for fluorescencent dye-stained DNA (ex.
EtBr)/protein (ex. SYPRO Ruby) gel imaging""Recombinant Human Palmitoyl-protein thioesterase 1_PPT1""Recombinant Human Palmitoyl-protein thioesterase 1_PPT1""Recombinant Human Palmitoyl-protein thioesterase 1_PPT1" Related articles to: HCV NS4A Protein (21_34) (JT strain) Formula C63H116N20O17 Sequence Gly_Ser_Val_Val_I le_Val_Gly_Arg_Ile_Ile_Leu_Ser_Gly_Arg
- Esophageal squamous cell carcinoma (ESCC) is a malignancy characterized by extensive epigenetic dysregulation. This study aims to develop a robust prognostic model utilizing epigenetic-related genes (ERGs) to improve survival prediction in ESCC patients, while simultaneously elucidating potential mechanisms underlying immune microenvironment modulation. - Source: PubMed
Publication date: 2025/10/23
Su YaniZhang MingZhang QiongWen PengfeiXu KeXie JialeWan XianjieLiu LinXu PengYang ZhiYang Mingyi - MicroRNA aberrations including that of miR-24-2 have been reported in various cancers. However, the target genes for miR-24-2 are yet to be identified and validated in invasive breast cancer and the triple-negative breast cancer (TNBC). Using approaches and gene expression analyses, we identified and validated the target genes of miR-24-2 in invasive breast cancer, majority of which were TNBC. We studied the translational potential of these target genes using berberine in a TNBC cell line. Differentially expressed genes targeted by miR-24-2 were identified and analyzed for their survival effects using the The Cancer Genome Atlas-Breast Invasive Carcinoma (-BRCA) samples. Furthermore, we carried out protein-protein interaction, Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, gene expression, and Kaplan-Meier survival analyses using common targets of miR-24-2 in invasive breast cancer/TNBC. We identified 11 biomarker candidate genes as crucial targets of miR-24-2. The survival of breast cancer patients was significantly associated with the low expressions of nine genes, including , , , , , , , , and SAP30-like (), and high expressions of two genes, and . These findings were validated by overexpressing miR-24-2 and assessing the expression pattern of these target genes in the TNBC MDA-MB-231 cells. miR-24-2 overexpression inhibited (by 20%; < 0.001) cell proliferation and sensitized the anticancer effect of berberine. In all, this study reports on the novel target genes of miR-24-2 in invasive breast cancer/TNBC, and that miR-24-2 sensitizes MDA-MB-231 cells to berberine. These data lend evidence for the translational potentials of miR-24-2 for invasive breast cancer diagnostic and therapeutic innovation. - Source: PubMed
Publication date: 2023/09/05
Ali MansoorBamezai Rameshwar N KSingh Rana P - Treatment of head and neck squamous cell carcinoma (HNSCC) is a substantial clinical challenge due to the high local recurrence rate and chemotherapeutic resistance. This project seeks to identify new potential biomarkers of prognosis prediction and precision medicine to improve this condition. A synthetic data matrix for RNA transcriptome datasets and relevant clinical information on HNSCC and normal tissues was downloaded from the Genotypic Tissue Expression Project and The Cancer Genome Atlas (TCGA). The necrosis-associated long-chain noncoding RNAs (lncRNAs) were identified by Pearson correlation analysis. Then 8-necrotic-lncRNA models in the training, testing and entire sets were established through univariate Cox (uni-Cox) regression and Lasso-Cox regression. Finally, the prognostic ability of the 8-necrotic-lncRNA model was evaluated via survival analysis, nomogram, Cox regression, clinicopathological correlation analysis, and receiver operating characteristic (ROC) curve. Gene enrichment analysis, principal component analysis, immune analysis and prediction of risk group semi-maximum inhibitory concentration (IC50) were also conducted. Correlations between characteristic risk score and immune cell infiltration, immune checkpoint molecules, somatic gene mutations, and anti-cancer drug sensitivity were analyzed. Eight necrosis-associated lncRNAs (AC099850.3, AC243829.2, AL139095.4, SAP30L-AS1, C5orf66-AS1, LIN02084, LIN00996, MIR4435-2HG) were developed to improve the prognosis prediction of HNSCC patients. The risk score distribution, survival status, survival time, and relevant expression standards of these lncRNAs were compared between low- and high-risk groups in the training, testing and entire sets. Kaplan-Meier analysis showed the low-risk patients had significantly better prognosis. The ROC curves revealed the model had an acceptable predictive value in the TCGA training and testing sets. Cox regression and stratified survival analysis indicated that the 8 necrosis-associated lncRNAs were risk factors independent of various clinical parameters. We recombined the patients into 2 clusters through Consensus ClusterPlus R package according to the expressions of necrotic lncRNAs. Significant differences were found in immune cell infiltration, immune checkpoint molecules, and IC50 between clusters, suggesting these characteristics can be used to evaluate the clinical efficacy of chemotherapy and immunotherapy. This risk model may serve as a prognostic signature and provide clues for individualized immunotherapy for HNSCC patients. - Source: PubMed
Shi YujingZhang YumengZuo NianWang LanSun XinchenLiang LiangJu MengyangDi Xiaoke - The zebra finch is one of the most commonly studied songbirds in biology, particularly in genomics, neuroscience and vocal communication. However, this species lacks a robust cell line for molecular biology research and reagent optimization. We generated a cell line, designated CFS414, from zebra finch embryonic fibroblasts using the SV40 large and small T antigens. This cell line demonstrates an improvement over previous songbird cell lines through continuous and density-independent growth, allowing for indefinite culture and monoclonal line derivation. Cytogenetic, genomic, and transcriptomic profiling established the provenance of this cell line and identified the expression of genes relevant to ongoing songbird research. Using this cell line, we disrupted endogenous gene sequences using S.aureus Cas9 and confirmed a stress-dependent localization response of a song system specialized gene, SAP30L. The utility of CFS414 cells enhances the comprehensive molecular potential of the zebra finch and validates cell immortalization strategies in a songbird species. - Source: PubMed
Publication date: 2022/03/14
Biegler Matthew TFedrigo OlivierCollier PaulMountcastle JacquelynHaase BettinaTilgner Hagen UJarvis Erich D - N6-methyladenosine (m6A) modifications play an essential role in tumorigenesis. These modifications modulate RNAs, including mRNAs and lncRNAs. However, the prognostic role of m6A-related lncRNAs in head and neck squamous cell carcinoma (HNSCC) is poorly understood. Based on LASSO Cox regression, enrichment analysis, univariate and multivariate Cox regression analysis, a prognostic risk model, and consensus clustering analysis, we analyzed 12 m6A-related lncRNAs in HNSCC sample data from The Cancer Genome Atlas (TCGA) database. We found 12 m6A-related lncRNAs in the training cohort and validated them in all cohorts by Kaplan-Meier and Cox regression analyses, revealing their independent prognostic value in HNSCC. Moreover, ROC analysis was conducted, confirming the strong predictive ability of this signature for HNSCC survival. GSEA and detailed immune infiltration analyses revealed specific pathways associated with m6A-related lncRNAs. In this study, a novel risk model including twelve genes (SAP30L-AS1, AC022098.1, LINC01475, AC090587.2, AC008115.3, AC015911.3, AL122035.2, AC010226.1, AL513190.1, ZNF32-AS1, AL035587.1 and AL031716.1) was built. It could accurately predict HNSCC outcomes and could provide new therapeutic targets for HNSCC patients. - Source: PubMed
Publication date: 2022/01/12
Zhou Liu-QingShen Jin-XiongZhou Jie-YuHu YaoXiao Hong-Jun